Overview

Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes

Status:
Unknown status

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

The investigators focused on patients with refractory acute leukemia or MDS and designed a phase 1 trial of escalated cladribine doses in the Cla-Flu-Bu RTC regimen using PK-guided myeloablative busulfan doses. This scheme allows combining different optimization of RTC experienced over years (Flu-Bu RTC, PK-guided myeloablative busulfan doses, a second purine analog cladribine) to approach a specific platform to treat refractory diseases.

Phase:

Phase 1

Details

Lead Sponsor:

Institut Paoli-Calmettes

Treatments:

Busulfan
Cladribine
Fludarabine
Fludarabine phosphate